SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, Papa Bear, BluSkies, StaleyCornell, buythebuy, mtlebomac
Search This Board: 
Last Post: 4/24/2017 7:02:59 AM - Followers: 831 - Board type: Free - Posts Today: 6



Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director


Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 

USRM - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/31/2017 04:02:24 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/17/2017 04:02:15 PM
#52397  Sticky Note This is the guy who is investing up Vita Nova Stocks 04/15/17 09:22:22 AM
#42457  Sticky Note THIS IS A MUST READ slam4202 03/30/17 07:05:37 AM
#42449  Sticky Note CEO BLOG / FDA "On regulatory news, BluSkies 03/30/17 04:51:30 AM
#26891  Sticky Note $USRM ALL IN ONE DD Post for Investors: TheHungryHippo 03/09/17 05:25:50 AM
#26168  Sticky Note Thoughts? BluSkies 03/07/17 09:49:57 PM
#54588   Great day to double your position if your damain22 04/24/17 07:20:35 AM
#54587   RISE AND SHINE! BUY EARLY! ACCUMULATE MORE! Broome 04/24/17 07:02:59 AM
#54586   Come back in 6-9 months then. emit 04/24/17 02:02:56 AM
#54585   To find fair market value. tothe 04/24/17 01:06:17 AM
#54584   USRM chart: Third consolidation step, measured move up. tothe 04/24/17 12:19:42 AM
#54583   bullsih 11JR11 04/24/17 12:16:23 AM
#54582   New to this website and this Board but tickerprice 04/23/17 11:25:39 PM
#54581   So, I'm your cryptic friend Work Harder 04/23/17 11:12:18 PM
#54580   Absolutely! USRM new found bottom now OTC QB. buythebuy 04/23/17 11:10:22 PM
#54579   ya think? packers10 04/23/17 11:09:10 PM
#54578   Sorry eheiser Work Harder 04/23/17 11:08:39 PM
#54577   USRM chart looks like it is consolidating for buythebuy 04/23/17 11:04:10 PM
#54576   You hear me Work Harder 04/23/17 10:44:54 PM
#54575   What ?! Good night bro. All good here eheiser 04/23/17 10:42:38 PM
#54574   I'll go against the blocks if need be Work Harder 04/23/17 10:40:21 PM
#54573   Right on. Good luck in your trades eheiser 04/23/17 10:37:59 PM
#54572   Do it, Work Harder 04/23/17 10:37:15 PM
#54571   What ?! No way man. That's too eheiser 04/23/17 10:36:42 PM
#54570   No 05's here beginning tomorrow morning Work Harder 04/23/17 10:33:57 PM
#54569   Let it go ? What's that mean ? eheiser 04/23/17 10:31:43 PM
#54568   No doubt ! eheiser 04/23/17 10:30:23 PM
#54567   Let it go Work Harder 04/23/17 10:30:05 PM
#54566   Pretty good analysis bro eheiser 04/23/17 10:28:47 PM
#54565   I'm bidding in that area. eheiser 04/23/17 10:27:34 PM
#54564   Signal Bay Work Harder 04/23/17 10:25:29 PM
#54563   Ya, I got here at .04 and got emit 04/23/17 10:19:21 PM
#54562   Wrong Watch N wait Work Harder 04/23/17 10:13:59 PM
#54561   You guys are too drunk on the kool tothe 04/23/17 10:11:33 PM
#54560   Just my take Work Harder 04/23/17 10:10:11 PM
#54559   USRM 60min chart I would put some powder tothe 04/23/17 10:01:36 PM
#54558   How are going to get that Work Harder 04/23/17 09:38:03 PM
#54557   I'll be putting my buy in at limit .0727 emit 04/23/17 09:29:44 PM
#54556   If I may, I'm Frank Work Harder 04/23/17 09:24:56 PM
#54555   LOL~You ain't makin fun of Ralph are you? ;) Kramden1 04/23/17 09:12:37 PM
#54554   USRM chart Pennant or falling wedge? tothe 04/23/17 09:06:43 PM
#54553   Nope who uses that ;? Work Harder 04/23/17 08:55:41 PM
#54552   Nope! ;) Kramden1 04/23/17 08:50:53 PM
#54551   Must be Work Harder 04/23/17 08:38:45 PM
#54550   We're all good imo. Rmat be here soon Hooey 04/23/17 08:37:53 PM
#54549   You're good Work Harder 04/23/17 08:32:56 PM
#54548   $USRM I agree big money coming here BoilerRoom 04/23/17 08:28:58 PM
#54547   $USRM Bwahahahahaha Weeeeeeeee!!! Load the boat folks!!! BoilerRoom 04/23/17 08:28:27 PM
#54546   Thought so Hooey 04/23/17 08:26:51 PM
#54545   Let me make it easy Work Harder 04/23/17 08:22:29 PM
#54543   So I bought lots at 3 cents but Hooey 04/23/17 08:09:38 PM
#54542   same group Work Harder 04/23/17 08:07:31 PM
#54541   Good friend Work Harder 04/23/17 07:53:02 PM
#54540   LMAO! No. But when it does >>>>> Kramden1 04/23/17 07:51:20 PM
#54539   You seeing a dip tomorrow Work Harder 04/23/17 07:46:39 PM
#54538   Didn't you hear me? Buy the F'n dip! Kramden1 04/23/17 07:43:54 PM